Advanced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Mario Sznol

Hematology | Oncology
Yale University
20 York St, 
New Haven, CT 
Offers Telehealth
43 Years of Experience
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Yale University
20 York St, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mario Sznol is a Hematologist and an Oncologist in New Haven, Connecticut. Dr. Sznol has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma.

His clinical research consists of co-authoring 158 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles and participated in 4 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Graduate Year
1982
Specialties
Hematology
Oncology
Licenses
Internal Medicine in CT
Hospital Affiliations
Yale-New Haven Hospital
Bridgeport Hospital
Lawrence & Memorial Hospital
Greenwich Hospital Association -
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

YALE UNIVERSITY
20 York St, New Haven, CT 06510

Additional Areas of Focus

Dr. Sznol has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: September 20, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Procedure, Drug, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
A Phase II Randomized Study of Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
A Phase II Randomized Study of Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
Enrollment Status: Terminated
Publish Date: February 20, 2024
Intervention Type: Drug, Device
Study Drugs: Atezolizumab, Tiragolumab
Study Phase: Phase 2
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drug: Enapotamab vedotin 
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
Enrollment Status: Completed
Publish Date: March 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: March 20, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

158 Total Publications

Role of high-dose interleukin-2 for melanoma in the age of cellular therapy.
Role of high-dose interleukin-2 for melanoma in the age of cellular therapy.
Journal: Journal for immunotherapy of cancer
Published: May 06, 2025
Similar Doctors
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Scott N. Gettinger
Oncology | Hematology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Scott N. Gettinger
Oncology | Hematology

Yale University

35 Park St, 
New Haven, CT 
 (0.1 miles away)
203-785-4191
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Gettinger is an Oncologist and a Hematologist in New Haven, Connecticut. Dr. Gettinger is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.

Roy S. Herbst
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Roy S. Herbst
Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Roy S. Herbst
Oncology

Yale University

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-688-4242
Languages Spoken:
English
See accepted insurances

Roy Herbst is an Oncologist in New Haven, Connecticut. Dr. Herbst is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Gamma Knife Radiosurgery.

Balazs Halmos
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Balazs Halmos
Hematology Oncology | Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Balazs Halmos
Hematology Oncology | Oncology

Montefiore Medical Center

111 E 210th St, 
Bronx, NY 
 (57.2 miles away)
718-920-4321
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Balazs Halmos is a Hematologist Oncology specialist and an Oncologist in Bronx, New York. Dr. Halmos is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sznol's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile